抗骨折药物疗效证据的脆弱性
该回顾性分析纳入27项在高影响力医学期刊发表、按1:1随机分配、报告统计学显著抗骨折疗效的3/4期随机对照试验,用脆弱指数(FI)和脆弱商数(FQ)评估证据稳健性。中位FI为9(IQR:4,19),相当于干预组增加约0.51%的骨折患者即可使疗效证据失去统计学显著性;60%的分析中失访人数超过相应FI。作者结论为现有抗骨折疗效随机对照试验证据高度脆弱,建议将FI、FI与失访的比较及FQ纳入临床指南制定和医患风险沟通。
要点
- 27项3/4期随机对照试验的中位脆弱指数为9(IQR:4,19),约相当于研究规模的0.51%。
- 60%的分析中失访人数超过相应脆弱指数。
- 罗莫佐单抗证据最稳健(FI:19.5;IQR:7.0,31.5),地舒单抗(4;3,17)与钙/维生素D补充(7.0;2.3,16.8)最低。
核心结论
- 现有抗骨折疗效的随机对照试验证据高度脆弱。
- 作者认为应将脆弱指数、其与失访的比较及脆弱商数纳入临床指南制定和医患风险沟通。
研究设计与样本
- 回顾性分析纳入27项在高影响力医学期刊发表、评估抗骨折疗效、按1:1比例分配至药物干预或对照、并报告统计学显著结果的3/4期随机对照试验。
- 使用脆弱指数(FI)和脆弱商数(FQ)评估结果的脆弱性;FI为使阳性分析结果逆转报告状态即消除统计学显著性所需的最少参与者数,FQ为FI与样本量的函数。
主要发现
- 中位FI为9(IQR:4,19),提示干预组增加9例骨折患者(约占研究规模的0.51%)即可消除已记录的抗骨折疗效证据。
- 60%的分析中失访参与者数超过相应FI。
- 抗骨折疗效证据最稳健者为罗莫佐单抗(FI:19.5;IQR:7.0,31.5),最低者为地舒单抗(4;3,17)和钙/维生素D补充(7.0;2.3,16.8)。
- 以骨折为主要终点指标的结果(14;11,33)或P值<.001的结果(26;18,42)中抗骨折疗效证据有所改善。
临床怎么用
- 作者认为应将FI、其与失访的比较及FQ纳入临床指南制定和医患风险沟通。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: A P value and statistical significance, conventionally considered for assessing an intervention's effectiveness, are usually misused and misinterpreted. OBJECTIVE: To quantify fragility of randomized controlled trial (RCT) evidence for anti-fracture efficacy. METHODS: This retrospective analysis included 27 phase 3/4 RCTs in high-impact medical journals which assessed anti-fracture efficacy, allocated participants in a 1:1 ratio to pharmacological intervention or control, and reported a statistically significant result. Fragility of the results were assessed using the Fragility Index (FI) and Fragility Quotient (FQ). FI is the minimum number of participants in a positive analysis result for whom reversing the reported status would eliminate statistical significance, while FQ is a function of FI to the sample size. RESULTS: The median FI was 9 (IQR: 4, 19), indicating that adding 9 fracture patients (∼0.51% of the study size) to the intervention group would eliminate the documented evidence of anti-fracture efficacy. Notably, the number of participants lost to follow-up exceeded the corresponding FI in 60% of analyses. The most robust evidence for anti-fracture efficacy was documented for romosozumab (FI: 19.5; IQR: 7.0, 31.5); whereas the least found for denosumab (4; 3, 17) and calcium/vitamin D supplementation (7.0; 2.3, 16.8). Anti-fracture efficacy evidence improved among the results that considered fractures the primary endpoint measure (14; 11, 33) or those with P value < .001 (26; 18, 42). CONCLUSION: The existing RCT evidence of anti-fracture efficacy is highly fragile. The FI, its comparison with loss to follow-up and FQ should be incorporated into clinical guideline development and doctor-patient risk communication.
引用
- Tran N, Tran TS, Nguyen TV, et al. Fragility of Evidence for the Efficacy of Anti-Fracture Medications. J Clin Endocrinol Metab. 2025. PMID: 40488289. doi:10.1210/clinem/dgaf332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。